ASX Announcement QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C • Vanderbilt Health to conduct clinical trial of HMBD-002 in Acute Myeloid Leukaemia (AML) patients. • Dr Michael Baker appointed as CEO and Managing Director. • Percheron and Invion to explore novel combination of VISTA...